Bolt Biotherapeutics, Inc.
NASDAQ:BOLT
0.6513 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 7.876 | 5.729 | 1.26 | 0.231 | 0.215 | 0 |
| Cost of Revenue
| 1.884 | 4.891 | 3.672 | 40.357 | 26.002 | 0.302 |
| Gross Profit
| 5.992 | 0.838 | -2.412 | -40.126 | -25.787 | -0.302 |
| Gross Profit Ratio
| 0.761 | 0.146 | -1.914 | -173.706 | -119.94 | 0 |
| Reseach & Development Expenses
| 59.658 | 73.123 | 75.655 | 40.357 | 26.002 | 9.42 |
| General & Administrative Expenses
| 22.53 | 22.927 | 18.393 | 9.056 | 5.182 | 2.209 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 22.53 | 22.927 | 18.393 | 9.056 | 5.182 | 2.209 |
| Other Expenses
| -61.542 | 0 | -6.084 | -11.745 | -0.042 | -0.153 |
| Operating Expenses
| 82.188 | 96.05 | 94.048 | 49.413 | 31.184 | 11.629 |
| Operating Income
| -76.196 | -90.321 | -92.788 | -49.182 | -30.969 | -11.629 |
| Operating Income Ratio
| -9.674 | -15.766 | -73.641 | -212.909 | -144.042 | 0 |
| Total Other Income Expenses Net
| 6.999 | 2.223 | -5.803 | -11.546 | 0.482 | -0.153 |
| Income Before Tax
| -69.197 | -88.098 | -98.591 | -60.728 | -30.487 | -11.589 |
| Income Before Tax Ratio
| -8.786 | -15.378 | -78.247 | -262.892 | -141.8 | 0 |
| Income Tax Expense
| 1.716 | -2.223 | 5.803 | 11.546 | -0.482 | 0.04 |
| Net Income
| -69.197 | -85.875 | -104.394 | -72.274 | -30.005 | -11.589 |
| Net Income Ratio
| -8.786 | -14.99 | -82.852 | -312.874 | -139.558 | 0 |
| EPS
| -1.83 | -2.3 | -2.79 | -1.99 | -0.85 | -1.23 |
| EPS Diluted
| -1.83 | -2.3 | -2.79 | -1.99 | -0.85 | -1.23 |
| EBITDA
| -74.312 | -88.655 | -85.511 | -36.826 | -30.592 | -11.174 |
| EBITDA Ratio
| -9.435 | -15.475 | -67.866 | -159.42 | -142.288 | 0 |